过去的一周,全球减肥药领域的两大巨头礼来(Eli Lilly)和诺和诺德(Novo Nordisk)接连爆出重磅新闻,从礼来发布替尔泊肽(tirzepatide商品名Zepbound)与司美格鲁肽(semaglutide商品名Wegovy)头对头研究的压倒性结果,到诺和诺德调整战略押注口服药、CEO突然宣布离职,都在一定程度上反映了当前市场竞争的白热化。司美格鲁肽的危机5月11日,礼来公布了...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.